|
 |
Drug derived from vitamin A slows lung cancer in mice
Source: (cancerfacts.com)
Wednesday, January 18, 2006
ST. LOUIS – Jan. 18, 2006 – A compound related to vitamin A shows promise of preventing or slowing tumor growth in mice prone to lung cancer, researchers say.
Led by Dr. Ming You, director of the Chemoprevention Program at the Siteman Cancer Center at Washington University, the researchers found that the compound, called bexarotene, also doesn't cause the severe skin irritations that have limited the use of other vitamin A derivatives in cancer therapies.
"In the cancer prevention field, you look for drugs that can be given to healthy patients who have a higher risk of developing cancer," Ming You said in a prepared statement. "These patients wouldn't want to take a medication that makes them feel sick when they don't have cancer. So the drugs should be very well-tolerated and not cause harmful side effects."
The ideal substance to prevent cancer would block tumor growth without causing unpleasant or dangerous side effects. In other studies, bexarotene showed some promise in cancer treatment. It extended survival in patients with non-small cell lung cancer, the most common type of lung cancer and one that has a five-year survival rate of less than 5 percent when diagnosed at the advanced stage.
In the current study, to be published in an upcoming issue of Oncogene, You, who is also professor of surgery, and Dr. Yian Wang, associate professor of surgery and their colleagues showed that lung-cancer-susceptible mice receiving non-toxic doses of bexarotene ended up with fewer and smaller benign and malignant tumors than mice that were not treated with bexarotene.
The researchers saw a reduction of almost 50 percent in terms of total amount of tumor in mice who were given bexarotene for 12 weeks after the animals had already developed benign tumors following injection of a lung carcinogen. Bexarotene also inhibited the progression of benign to malignant tumors by about 50 percent. The mice were engineered to have the genetic alterations seen in human lung cancers, so they readily develop lung cancer when given known lung carcinogens.
"Seeing this magnitude of response in such a strongly susceptible mouse suggests bexarotene is a potentially viable lung cancer prevention candidate," You says.
Members of the vitamin A family called retinoids have long been studied as potential chemotherapeutic agents because they help regulate cell division, growth and specialization. A new class of these vitamin A relatives has been created that includes bexarotene. These substances are called the rexinoids, so named because they are attracted to a molecule on cell surfaces called RXR.
Rexinoids tend to be much less toxic than retinoids, and among them bexarotene has so far shown the most promise as a chemopreventive medicine. However, although it causes far fewer side effects, bexarotene does have the effect of increasing blood lipid levels in many patients. Patients taking bexarotene often need to take a drug to lower their cholesterol and triglyceride levels.
A new rexinoid called UAB30, just becoming available for laboratory studies, seems to have the potential to reduce even the high-lipid side effect.
"We will be testing this new compound, too, and if it turns out to be effective, these rexinoids will most likely become candidates for clinical trials in patients with precancerous nodules or bronchial dysplasia," You says. "If the trials show reduction of cancers, I think these drugs may well become routinely used for lung cancer prevention."
Prevention is considered the key to reducing the impact of lung cancer, which accounts for 32 percent of cancer deaths in men and 25 percent of cancer deaths in women. The majority of lung cancer patients are not diagnosed until their cancer has reached an advanced stage, and current treatment regimens do not substantially improve the outcome for most of these patients.
"Advanced or metastatic cancer is sort of a genius at adapting," You says. "By that point, the cancer cells that have survived have overcome so many obstacles and gained so many abilities that they are difficult to kill. They have a very unstable genome that can change quickly to resist the treatments we use. It's best if you attack cancer in its infancy or at the precancerous stage. The earlier the better."
Copyright © 2001, 2002, 2003, 2004, 2005 NexCura, Inc. All rights reserved. Republication or redistribution of cancerfacts.com content, including by framing or similar means, is expressly prohibited without the prior written consent of NexCura. NexCura® is a registered trademark and cancerfacts.com™ is a trademark of NexCura, Inc. or its affiliates. Copyright © 2001, 2002, 2003, 2004, 2005. All rights reserved. This information is for educational purposes only.
|
|
|
|
|
|
